Navigation Links
Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Date:5/24/2012

SAN DIEGO, May 24, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $50 million in additional equity funding from existing investor, Leucadia National Corporation. This funding was made upon the exercise of Series G preferred stock warrants previously held by Leucadia and brings the total funding raised by the company since inception to more than $280 million.

(Logo: http://photos.prnewswire.com/prnh/20120524/LA12228LOGO)

This funding followed an independent Data Monitoring Committee (DMC) review of safety data from the first 122 patients enrolled in the Phase 2b trauma study involving MP4OX, Sangart's novel oxygen therapeutic agent (OTA) developed to perfuse and oxygenate tissues at risk for ischemia in patients experiencing hemorrhagic shock. After evaluating the data, the DMC unanimously recommended that the study should continue without any modification.

"We are encouraged by this level of support from our existing investors, who recognize the clinical potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our unique MP4 gas-delivery platform, focused on developing therapies for patients in crisis who are experiencing ischemia and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease."

The funds will be used to advance the development of the MP4OX product in severe traumatic hemorrhagic shock and the MP4CO product in sickle cell disease.  

About MP4
Sangart's unique MP4 gas-delivery platform is being used to dev
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
2. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
3. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
4. Sangart, Inc. Completes Series F Funding Round
5. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
6. Cerecor Raises $22 Million Series A Financing
7. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
8. Cowen Healthcare Royalty Partners Raises $1 Billion
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Global ... by 2019 growing at an estimated CAGR of ... for healthy food products with least ecological impacts, ... mineral fertilizers to boost crop yield more effectively ... products that can improve the return on investments. ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) ... to serve in a newly created position of ... Gavin will be responsible for managing the operations of ... business acquired in July 2014 and the recently acquired ... -based ProteinSimple develops and commercializes proprietary systems and ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... coming out of California, but the failure of flight communications ... of the weirdest. , ,The radio system used by controllers ... snit when its regular monthly maintenance wasnt performed and shut ... couldnt talk to them, even as the planes converged well ...
... raised the premise that in the early years of biotech it ... health care. , ,Theres a thread drawn to the early ... making money but about expressing what was going on in society ... money and both have become industries that have become mainstream. , ...
... likely be a popular spot for wireless use. Source: Fitchburg ... green mixed-use development, is now home to a free wireless ... Systems put up, provides wireless access to about 16 ... prairie with trails and a large pavilion. , ,Besides Berbee, ...
Cached Biology Technology:Proactive nightmares 2Biotech IPOs bring in encouraging sums 2Biotech IPOs bring in encouraging sums 3Fitchburg tech campus offers free wireless access 2
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... Nov. 3, 2014 Research and Markets ... Therapy - Technologies, Markets and Companies" to their offering. ... technologies and methods, which have already started to play an ... transplantation is replacing the old fashioned bone marrow transplants. Role ... is bound to become a part of medical practice. ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... its host, the respiratory pathogen Pseudomonas aeruginosa takes ... adds three small molecules to turn it into a key ... be published May 7 in mBio , the online ... Emory University School of Medicine, the University of Virginia, and ...
... , On May 3, 2013, the NOAA GOES infrared and visible ... of smoke from the fire. The smoke plume is seen blowing ... 17 seconds and shows the smoke plume from May 3 at ... created by the NASA GOES Project, located at NASA,s Goddard Space ...
... MARC (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine (ACSM) 60th Annual Meeting & 4th ... from May 28 June 1, 2013. These awards ... and scientists from underrepresented groups into the mainstream of ...
Cached Biology News:Pathogen turns protein into a virulence factor in 1 easy step 2Pathogen turns protein into a virulence factor in 1 easy step 3MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress 2
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic ... of the human WNT2B/WNT13 protein. ... human mouse and rat WNT2B/WNT13 proteins. ... isoforms. Reactivity: Mouse Human Rat ...
Request Info...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Biology Products: